Recombinant Thrombomodulin Used to Successfully Treat Cronkhite-Canada Syndrome with Disseminated Intravascular Coagulation due to Sepsis in a Compromised Patient

Abstract

Cronkhite-Canada syndrome (CCS) is a rare non-inherited disease characterized by gastrointestinal polyposis, chronic diarrhea, ectodermal dysplasia, skin hyperpigmentation, hair loss and nail atrophy. Although the efficacy of corticosteroid and immunomodulatory agents has been demonstrated, no standard therapy regimen has been established, and the prognosis of CCS is still poor due to various complications. We here in report a CCS patient complicated with severe sepsis and disseminated intravascular coagulation who was successfully treated by combined modality therapies, including recombinant human soluble thrombomodulin.

Comprehensive treatment of Cronkhite-Canada syndrome: A case report and literature review

“…[ 23 ] Approximately 12.5% of polyps have been reported to undergo malignant transformation, emphasizing the need to closely monitor these patients. [ 24 ]…”

“…[23] Approximately 12.5% of polyps have been reported to undergo malignant transformation, emphasizing the need to closely monitor these patients. [24] The diagnosis of CCS is based on medical history, physical examination, endoscopic examination of gastrointestinal polyps and histopathology. Digestive endoscopy is the most direct examination method for this disease.…”